LSTA on Nasdaq
Caladrius Biosciences
Biopharmaceutical company in New Jersey, United States
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.3 From Wikipedia, CC BY-SA 4.0
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with BIOXYTRAN, INC, Clene Inc. or NOMAD POWER SOLUTIONS, INC., or pick any stock.
- TickerLSTA on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersNew York City1
- Websitewww.caladrius.com
- Legal formDelaware corporation1
- Incorporated inDE4
- Business address110 Allen Road, Second Floor, Basking Ridge, Nj 079204
- Filer categoryNon-accelerated filer, Smaller reporting company4
See how the biggest companies compare on our leaderboards
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Income tax100¢$962.0K
Out of $170.0K in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $170.0K | $1.0M |
| Research and development | $7.9M | $11.3M |
| General and administrative | $10.4M | $12.1M |
| Operating expenses | $18.4M | $23.4M |
| Operating loss | -$18.2M | -$22.4M |
| Investment income, net | $806.0K | $1.9M |
| Other expense, net | -$145.0K | -$257.0K |
| Total other income | $661.0K | $1.6M |
| Net loss before benefit from income taxes and noncontrolling interests | -$17.5M | -$20.8M |
| Benefit from income taxes | -$962.0K | -$798.0K |
| Net loss | -$16.6M | -$20.0M |
| Less - net income (loss) attributable to noncontrolling interests | $0 | $0 |
| Net loss attributable to Lisata Therapeutics, Inc. common stockholders | -$16.6M | -$20.0M |
| Lisata Therapeutics, Inc. common stockholders - basic (in dollars per share) | -$1.91 | -$2.40 |
| Lisata Therapeutics, Inc. common stockholders - diluted (in dollars per share) | -$1.91 | -$2.40 |
| Basic (in shares) | 8.7M shares | 8.3M shares |
| Diluted (in shares) | 8.7M shares | 8.3M shares |
Every line of the balance sheet in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $16.0M | $16.2M | |
| Marketable securities | $0 | $15.0M | |
| Accounts receivable | $0 | $900.0K | |
| Prepaid and other current assets | $1.7M | $2.4M | |
| Total current assets | $17.7M | $34.6M | |
| Property and equipment, net | $18.0K | $72.0K | |
| Acquired license-intangible, net | $0 | $192.0K | |
| Other assets | $23.0K | $160.0K | |
| Total assets | $17.7M | $35.0M | |
| Accounts payable | $1.0M | $1.3M | |
| Accrued liabilities | $2.1M | $4.3M | |
| Total current liabilities | $3.1M | $5.6M | |
| Other long-term liabilities | $72.0K | $72.0K | |
| Total liabilities | $3.1M | $5.7M | |
| Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,834,613 and 8,409,582 shares, at December 31, 2025 and December 31, 2024, respectively; and outstanding, 8,833,875 and 8,408,844 shares, at December 31, 2025 and December 31, 2024, respectively | $9.0K | $8.0K | |
| Additional paid-in capital | $580.2M | $578.4M | |
| Treasury stock, at cost; 738 shares at December 31, 2025 and December 31, 2024 respectively | -$708.0K | -$708.0K | |
| Accumulated deficit | -$564.7M | -$548.1M | |
| Accumulated other comprehensive loss | -$37.0K | -$81.0K | |
| Total Lisata Therapeutics, Inc. stockholders' equity | $14.9M | $29.6M | |
| Non-controlling interests | -$254.0K | -$254.0K | |
| Total equity | $14.6M | $29.3M | $47.9M |
| Total liabilities, non-controlling interests and stockholders' equity | $17.7M | $35.0M | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | |
| Common stock, shares, issued (in shares) | 8.8M shares | 8.4M shares | |
| Common stock, shares, outstanding (in shares) | 8.8M shares | 8.4M shares | |
| Treasury stock (in shares) | 738 shares | 738 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$16.6M | -$20.0M |
| Share-based compensation expense | $1.2M | $1.7M |
| Depreciation and amortization | $146.0K | $174.0K |
| Loss from equity method investment | $0 | $130.0K |
| Impairment of non-financial asset | $127.0K | $0 |
| Amortization/accretion on marketable securities | -$75.0K | -$455.0K |
| Allowance for credit losses | $500.0K | $0 |
| Accounts receivable | $401.0K | -$900.0K |
| Prepaid and other current assets | $742.0K | $852.0K |
| Other assets | $140.0K | $170.0K |
| Accounts payable, accrued liabilities and other liabilities | -$2.6M | -$995.0K |
| Net cash used in operating activities | -$15.9M | -$19.4M |
| Purchase of marketable securities | -$9.2M | -$55.7M |
| Sales of marketable securities | $24.3M | $69.1M |
| Investment in Impilo Therapeutics | $0 | -$130.0K |
| Purchases of property and equipment | -$28.0K | $0 |
| Net cash provided by investing activities | $15.1M | $13.2M |
| Proceeds from exercise of options | $8.0K | $0 |
| Tax withholding payments on net share settlement equity awards | -$253.0K | -$274.0K |
| Net proceeds from issuance of common stock | $844.0K | $68.0K |
| Net cash provided by (used in) financing activities | $599.0K | -$206.0K |
| Effect of exchange rate changes on cash | $11.0K | -$55.0K |
| Net decrease in cash and cash equivalents | -$253.0K | -$6.4M |
Former names
Timeline
- 2006Founded Founded1
Recent filings
- Oct 14, 20268-K
- Oct 7, 2026PRE 14A
- Oct 2, 2026D
- Sep 28, 20263
- Sep 28, 20263
- Sep 17, 20268-K
- Aug 26, 2026SCHEDULE 13G
- Aug 6, 202610-Q
- Aug 4, 20268-K
- Jul 28, 2026SC TO-T/A
- Jul 24, 20268-K
- Jul 21, 2026SC 14D9/A
- Jul 17, 2026SC TO-T/A
- Jul 17, 2026SC 14D9/A
- Jul 17, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.caladrius.com1
- WikipediaLisata Therapeutics
- WikidataQ6994181
- SEC EDGARCIK 320017
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3WikipediaCaladrius Biosciences on Wikipedia
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12